Vaniqa (Eflornithine): Uses, Dosage & Side Effects

What Is Vaniqa and What Is It Used For?

Vaniqa contains the active substance eflornithine, a compound that was originally developed as an antiprotozoal agent for the treatment of African trypanosomiasis (sleeping sickness). During clinical research, scientists discovered that eflornithine also has a remarkable effect on hair growth when applied topically. This discovery led to the development of Vaniqa cream, which received marketing authorization from the European Medicines Agency (EMA) and approval from the U.S. Food and Drug Administration (FDA) for the treatment of facial hirsutism in women.

Hirsutism is a condition characterized by excessive hair growth in areas where hair is typically minimal or absent in women, most notably the face. It affects an estimated 5–10% of women of reproductive age worldwide, according to the Endocrine Society. The condition can be caused by elevated androgen levels, polycystic ovary syndrome (PCOS), certain medications, or it may be idiopathic (without identifiable cause). Regardless of the underlying cause, hirsutism can have a significant psychological impact, affecting self-esteem, body image, and quality of life.

Eflornithine works by irreversibly inhibiting ornithine decarboxylase (ODC), an enzyme that catalyzes the first and rate-limiting step in the biosynthesis of polyamines. Polyamines—putrescine, spermidine, and spermine—are essential for cell proliferation and differentiation, including the growth and division of hair follicle cells. By blocking ODC activity in the hair follicle, eflornithine reduces the rate of hair growth without destroying the follicle itself or removing existing hair.

It is important to understand that Vaniqa is not a hair removal product. It does not dissolve, pull out, or destroy hair. Instead, it slows the rate at which new hair grows after removal. For this reason, women using Vaniqa should continue their preferred method of hair removal—such as shaving, tweezing, threading, or waxing—and will typically notice that hair regrows more slowly and may become finer over time. Clinical trials have demonstrated statistically significant improvements in physician-assessed measures of facial hair growth compared to placebo after 24 weeks of treatment.

Vaniqa is available in tubes containing 15 g, 30 g, or 60 g of cream, though not all pack sizes may be marketed in every country. The cream is white to off-white in appearance and is manufactured by Almirall Hermal GmbH in Germany, with the marketing authorization held by Almirall, S.A. in Barcelona, Spain.

What Should You Know Before Using Vaniqa?

Contraindications

Vaniqa must not be used if you have a known allergy (hypersensitivity) to eflornithine or to any of the other ingredients in the cream. The excipients include cetostearyl alcohol, macrogol cetostearyl ether, dimethicone, glyceryl stearate, macrogol stearate, methylparaben (E218), liquid paraffin, phenoxyethanol, propylparaben (E216), purified water, and stearyl alcohol. Small amounts of sodium hydroxide (E524) may also be added to adjust pH. If you have previously experienced a skin reaction to any of these ingredients, you should not use this product.

It is particularly important to note that cetostearyl alcohol and stearyl alcohol can cause local skin reactions such as contact dermatitis. Additionally, methylparaben (E218) and propylparaben (E216) may cause allergic reactions, which may sometimes be delayed. If you have a history of sensitivity to parabens or fatty alcohols, discuss this with your doctor or pharmacist before starting treatment.

Warnings and Precautions

Before using Vaniqa, talk to your doctor or pharmacist, especially if you have any of the following conditions or circumstances:

• Kidney disease: Since eflornithine is primarily excreted by the kidneys (when absorbed systemically), impaired renal function could theoretically lead to higher systemic levels. Although topical absorption is minimal (approximately 1% of the applied dose), your doctor should be aware of any kidney problems.
• Liver disease: Similarly, hepatic impairment should be reported to your healthcare provider before starting treatment, as it may affect the metabolism of the small amount of drug that enters the systemic circulation.
• Underlying hormonal conditions: Excessive facial hair growth can be a symptom of underlying medical conditions such as polycystic ovary syndrome (PCOS), hormone-producing tumors, or hormonal imbalances. Your doctor should evaluate and address any underlying cause before or alongside prescribing Vaniqa.
• Medications that promote hair growth: Certain medications are known to cause or worsen hirsutism, including ciclosporin (used after organ transplantation), glucocorticoids (for rheumatic or allergic conditions), minoxidil (for high blood pressure or hair loss), phenobarbital (for seizures), and hormone replacement therapy with androgenic effects. Inform your doctor about all medications you are taking.

Pregnancy and Breastfeeding

Pregnancy: Vaniqa should not be used during pregnancy. Although systemic absorption from topical application is low, the safety of eflornithine in pregnant women has not been established through adequate clinical studies. Animal reproductive toxicity studies have shown some effects at high systemic doses, and the precautionary principle applies. If you become pregnant while using Vaniqa, discontinue the cream and consult your healthcare provider. You should use an alternative method for managing facial hair during pregnancy.

Breastfeeding: Vaniqa should not be used while breastfeeding. It is not known whether eflornithine is excreted in human breast milk following topical application. Given the lack of data, the use of Vaniqa during breastfeeding is not recommended.

Children and Adolescents

Vaniqa is not recommended for use in individuals under 18 years of age. The safety and efficacy of eflornithine cream in this age group have not been established in clinical trials. If a teenager is experiencing excessive facial hair growth, a doctor should evaluate for underlying hormonal causes and consider age-appropriate management options.

Driving and Using Machines

Vaniqa is not expected to have any effect on the ability to drive or operate machinery. Since it is applied topically to the face and has minimal systemic absorption, there are no known central nervous system effects that would impair alertness or coordination.

How Does Vaniqa Interact with Other Drugs?

Because eflornithine cream is applied topically and only approximately 1% of the applied dose reaches the systemic circulation, clinically significant drug–drug interactions are not expected. However, there are some practical considerations when using Vaniqa alongside other products or medications.

Always inform your doctor or pharmacist about all medications you are currently taking, have recently taken, or plan to take, including prescription and over-the-counter medicines, herbal products, and supplements. This is particularly important if you are using other topical treatments on the same facial areas where Vaniqa is applied.

Unlike many oral medications, Vaniqa does not undergo hepatic metabolism to a clinically significant degree after topical application, so interactions with CYP450 enzyme inducers or inhibitors are not a concern. The primary route of elimination of absorbed eflornithine is renal excretion of the unchanged drug.

What Is the Correct Dosage of Vaniqa?

Always use Vaniqa exactly as your doctor has prescribed. If you are unsure about any aspect of the application, consult your doctor or pharmacist for guidance. The following dosing information is based on the approved product labeling and clinical trial protocols.

Adults (Women Over 18 Years)

Step-by-step application instructions:

1. Cleanse and dry the skin areas where you intend to apply the cream. The skin should be clean and completely dry before application.
2. If you have recently shaved or used another hair removal method, wait at least 5 minutes before applying Vaniqa. Applying the cream to freshly shaved or irritated skin may cause stinging or burning.
3. Squeeze a thin layer of cream onto your fingertip and apply it to the affected areas of the face and adjacent chin.
4. Rub in thoroughly until no visible residue of cream remains on the treated areas. This ensures optimal contact between the active ingredient and the hair follicles.
5. Wash your hands immediately after application to avoid inadvertently transferring the cream to other body areas or the eyes.
6. Do not wash the treated facial areas for at least 4 hours after application. This allows sufficient time for the eflornithine to be absorbed into the skin and reach the hair follicles.
7. Wait at least 5 minutes before applying makeup, sunscreen, or other facial products to the treated areas.

Dose Reduction for Irritation

If you experience irritation such as stinging, burning, or redness at the application site, reduce the frequency of application to once daily until the irritation resolves. If the irritation persists despite reducing the frequency, discontinue use and contact your doctor for advice. Do not attempt to compensate for the reduced frequency by applying a thicker layer of cream.

Children and Adolescents

Vaniqa is not recommended for individuals under 18 years of age. No dosage recommendations can be made for this population due to the absence of adequate safety and efficacy data.

Elderly Patients

No specific dose adjustment is required for elderly patients. However, as renal function may decline with age, elderly women with known kidney impairment should discuss the use of Vaniqa with their doctor. The standard twice-daily application regimen applies unless otherwise directed by a healthcare provider.

Missed Dose

If you forget to apply Vaniqa at the scheduled time, apply the cream as soon as you remember. However, you must wait at least 8 hours before the next application. Do not apply a double amount to make up for a missed dose. Simply resume your regular twice-daily schedule.

Overdose

If you apply too much cream to the skin, it is unlikely to cause harm. Simply wipe off the excess cream. However, if Vaniqa is accidentally ingested (swallowed), seek medical attention immediately. Contact your local poison control center or go to the nearest emergency department. While the topical formulation is designed for external use only, ingestion of significant amounts could potentially lead to systemic effects of eflornithine, including gastrointestinal disturbances.

Treatment Timeline and Expectations

What Are the Side Effects of Vaniqa?

Like all medicines, Vaniqa can cause side effects, although not everyone gets them. The side effects associated with eflornithine cream are predominantly cutaneous (skin-related) and generally mild in severity. Most side effects are localized to the application site and tend to resolve on their own without the need to discontinue treatment. In clinical trials, the overall incidence of adverse events was similar between the eflornithine and placebo groups, with skin-related events being the most frequently reported.

The frequency categories below follow the standard medical classification system used by the EMA and regulatory authorities worldwide:

If you experience any side effects that become severe, bothersome, or persistent, or if you notice any effects not listed above, contact your doctor or pharmacist. You can also report suspected side effects to your national pharmacovigilance authority to help ensure ongoing monitoring of the medicine’s benefit–risk profile.

How Should You Store Vaniqa?

Proper storage of medications is essential to maintain their effectiveness and safety. Follow these guidelines for storing Vaniqa cream:

• Temperature: Store at or below 25°C (77°F). Do not freeze. Do not expose to excessive heat or direct sunlight, as this may degrade the active ingredient and alter the cream’s consistency.
• After opening: Once a tube of Vaniqa has been opened, any remaining cream should be discarded after 6 months, regardless of the printed expiry date. The in-use shelf life is shorter than the unopened shelf life because exposure to air and contaminants can affect stability.
• Cap closure: Always ensure the tube’s cap is tightly screwed on after each use to prevent contamination and drying out of the cream.
• Keep out of reach of children: Store Vaniqa in a safe place where children cannot access it. Accidental ingestion could be harmful.
• Expiry date: Do not use Vaniqa after the expiry date printed on the carton and the bottom of the tube. The expiry date refers to the last day of that month.
• Disposal: Do not dispose of medicines via household waste or down the drain. Ask your pharmacist how to properly dispose of medicines that are no longer needed. These measures help protect the environment.

What Does Vaniqa Contain?

Understanding the full composition of a medication is important for identifying potential allergens and making informed decisions about its use. Vaniqa cream contains the following ingredients:

Active Ingredient

Each gram of cream contains 115 mg of eflornithine (equivalent to 11.5% w/w), present as eflornithine hydrochloride monohydrate. Eflornithine is a difluoromethyl analog of ornithine that irreversibly inhibits ornithine decarboxylase, the enzyme responsible for catalyzing the decarboxylation of ornithine to putrescine, the first step in polyamine synthesis.

Inactive Ingredients (Excipients)

The cream is white to off-white in color and has a smooth, non-greasy texture that absorbs readily into the skin. It does not have a strong odor. The formulation is designed to deliver eflornithine to the hair follicles within the dermis while minimizing systemic absorption.